WP
AQST icon

Woodline Partners’s Aquestive Therapeutics AQST Stock Holding History

Woodline Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-407,661
Closed -$1.35M – 883
2025
Q2 		$1.35M Hold
407,661
– – 0.01% 775
2025
Q1 		$1.18M Sell
407,661
-1,653
-0.4% -$5K 0.01% 748
2024
Q4 		$1.46M Sell
409,314
-406,938
-50% -$1.88M 0.01% 701
2024
Q3 		$4.06M Buy
816,252
+215,293
+36% +$838K 0.03% 411
2024
Q2 		$1.56M Buy
600,959
+367
+0.1% +$1.23K 0.01% 439
2024
Q1 		$2.56M Buy
+600,592
New +$2M 0.02% 413

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Woodline Partners's AQST Position: Q3 2025 in Review

Woodline Partners sold out of Aquestive Therapeutics (AQST) in Q3 2025, closing a stake of 407,661 shares — an estimated $1.35M sold.

Woodline Partners first reported a position in AQST in Q1 2024 and held it in 6 quarters. The position peaked at $4.06M in Q3 2024. 152 funds tracked by Wall St. Rank hold AQST as of Q3 2025.

  • Woodline Partners reported no remaining Aquestive Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 407,661 Aquestive Therapeutics shares in Q3 2025, an estimated $1.35M.
  • Woodline Partners first reported a position in Aquestive Therapeutics in Q1 2024 and held it in 6 quarters.
  • Woodline Partners's Aquestive Therapeutics position peaked at $4.06M in Q3 2024.
  • 152 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.